Results of 2022 Annual General Meeting

RNS Number : 4909O

Ergomed plc

10 June 2022

 

PRESS RELEASE

Results of 2022 Annual General Meeting

Guildford, 10 June 2022: Ergomed plc (AIM: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today.  All Resolutions were duly passed.

Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:

Resolution number	R esolution	Votes for	Votes against	Abstentions
1	Accounts	40,070,518	0	1,492,956
2	Reappoint auditor	41,493,555	69,125	794
3	Reappoint John Dawson	41,454,634	107,895	945
4	Reappoint Mark Enyedy	34,200,041	7,362,488	945
5	Reappoint Michael Spiteri	32,439,508	9,123,278	688
6	Allot securities	39,399,013	2,163,803	658
7	Pre-emption rights	39,808,724	1,754,493	257
8	Pre-emption rights	39,699,675	1,863,542	257
9	Amendment to Articles of Association	41,563,066	0	408

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

Ergomed's Board engage with the Company's shareholders and other stakeholders to understand their views. Whilst all resolutions were passed, shareholders representing over 20% of votes cast voted against Resolution 5 and the Board will re-engage with them to better understand their position.

ENDS

Enquiries :

Ergomed plc     Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis      Tel: [phone]

Freddie Barnfield / Euan Brown (Nominated Adviser) 

James Black (Broker) 

Peel Hunt LLP    Tel: [phone]

James Steel / Dr Christopher Golden

Consilium Strategic Communications   Tel: [phone]

Chris Gardner / Matthew Neal   [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

 

END

 

 

RAGEAEKEFFPAEFA